151 related articles for article (PubMed ID: 9248730)
1. Cardiovascular effects of sulphonylurea derivatives.
Smits P
Diabetologia; 1997 Jul; 40 Suppl 2():S160-1. PubMed ID: 9248730
[No Abstract] [Full Text] [Related]
2. Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
Howes LG
Diabetes Obes Metab; 2000 Apr; 2(2):67-73. PubMed ID: 11220526
[No Abstract] [Full Text] [Related]
3. Cardiovascular effects of sulphonylurea derivatives.
Smits P; Bijlstra PJ; Russel FG; Lutterman JA; Thien T
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S55-9. PubMed ID: 8864641
[TBL] [Abstract][Full Text] [Related]
4. [Glimepiride].
Nakamura N
Nihon Rinsho; 2002 Sep; 60 Suppl 9():351-6. PubMed ID: 12387017
[No Abstract] [Full Text] [Related]
5. Potassium channels in the cardiovascular system.
Pogátsa G
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S91-8. PubMed ID: 8529523
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
7. ATP-sensitive K+ channels and insulin secretion: their role in health and disease.
Ashcroft FM; Gribble FM
Diabetologia; 1999 Aug; 42(8):903-19. PubMed ID: 10491749
[No Abstract] [Full Text] [Related]
8. [ATP-sensitive potassium channels and substances affecting them].
Pospísilová Y
Vnitr Lek; 1998 Jul; 44(7):435-8. PubMed ID: 9748883
[TBL] [Abstract][Full Text] [Related]
9. [Sulfonylurea drugs for type 2 diabetes].
Toyota T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015
[No Abstract] [Full Text] [Related]
10. [Pharmacology of glimepiride].
Satoh Y
Nihon Rinsho; 1997 Nov; 55 Suppl():147-51. PubMed ID: 9434459
[No Abstract] [Full Text] [Related]
11. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?
Smits P; Thien T
Diabetologia; 1995 Jan; 38(1):116-21. PubMed ID: 7744216
[TBL] [Abstract][Full Text] [Related]
12. Haemodynamic and other effects of sulphonylurea drugs on the heart.
Végh A; Papp JG
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S43-53. PubMed ID: 8864640
[TBL] [Abstract][Full Text] [Related]
13. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Bijlstra PJ; Lutterman JA; Russel FG; Thien T; Smits P
Diabetologia; 1996 Sep; 39(9):1083-90. PubMed ID: 8877293
[TBL] [Abstract][Full Text] [Related]
14. Oral hypoglycemic agents and the pregnant diabetic: "from bench to bedside".
Langer O
Semin Perinatol; 2002 Jun; 26(3):215-24. PubMed ID: 12099312
[TBL] [Abstract][Full Text] [Related]
15. [24 years later....].
Brogard JM
Rev Med Interne; 1998 Oct; 19(10):751-2. PubMed ID: 9827453
[No Abstract] [Full Text] [Related]
16. [Retrolective study design -- a new tool of evidence-based medicine].
Martin S
Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S86-90. PubMed ID: 15988675
[No Abstract] [Full Text] [Related]
17. Sulphonylureas, magnesium and cardiac K+ ATP channels.
Matz R
Diabetologia; 2000 Aug; 43(8):1080-1. PubMed ID: 10990091
[No Abstract] [Full Text] [Related]
18. Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.
Artini D; Abbiati R; Orsini G; Parenti MA; Bloch K; Daturi S; Mandelli V
Diabetologia; 1973 Sep; ():311-6. PubMed ID: 4204091
[No Abstract] [Full Text] [Related]
19. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
Loubatiéres A; Mariani MM; Ribes G; Alric R
Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
[No Abstract] [Full Text] [Related]
20. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
